Piqray FDA Approval History
Last updated by Judith Stewart, BPharm on July 1, 2019.
Piqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR positive, HER2-negative, PIK3CA-mutated breast cancer.
Development Timeline for Piqray
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.